No go for Zosano as FDA knockback triggers suspension of transdermal migraine patch program

[cafead]

via Zosano Pharma’s headaches are intensifying. With the FDA again knocking back its transdermal migraine patch, the biotech has suspended its M207 program and made more layoffs to preserve its dwindling cash reserves.

article source